NOVEL STABLE HIGH-CONCENTRATION FORMULATION FOR ANTI-FXIA ANTIBODIES
The present invention refers to novel liquid pharmaceutical high-concentration formulations particularly suitable for subcutaneous administration comprising human antibodies against coagulation factor FXIa as active ingredient, especially those described in WO2013167669, which are stable as liquid f...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | HEKE, STEFAN VEURINK, MARIEKE PLITZKO, MATTHIAS GOMBERT, NIKLAS KLAK, ALEXANDER SCHNEID, STEFAN CHRISTIAN |
| description | The present invention refers to novel liquid pharmaceutical high-concentration formulations particularly suitable for subcutaneous administration comprising human antibodies against coagulation factor FXIa as active ingredient, especially those described in WO2013167669, which are stable as liquid formulations over a long period. The invention also refers to lyophilizates of the specified liquid formulation with reduced reconstitution time and also to the use of these formulations in the therapy and prophylaxis of thrombotic or thromboembolic disorde.
La présente invention concerne de nouvelles formulations pharmaceutiques liquides à haute concentration particulièrement appropriées pour une administration sous-cutanée comprenant des anticorps humains contre le facteur de coagulation FXIa en tant que principe actif, en particulier ceux décrits dans la demande de brevet WO2013167669, qui sont stables en tant que formulations liquides sur une longue période. L'invention concerne également des lyophilisats de la formulation liquide spécifiée avec un temps de reconstitution réduit ainsi que l'utilisation de ces formulations dans la thérapie et la prophylaxie de troubles thrombotique ou thromboembolique. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3105256A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3105256A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3105256A13</originalsourceid><addsrcrecordid>eNrjZHDx8w9z9VEIDnF08nFV8PB099B19vdzdvULCXIM8fT3U3DzD_IN9YGzFRz9Qjx13SI8HcEsJ38XT9dgHgbWtMSc4lReKM3NoODmGuLsoZtakB-fWlyQmJyal1oS7-xobGhgamRq5mhoTIQSABK8K1o</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>NOVEL STABLE HIGH-CONCENTRATION FORMULATION FOR ANTI-FXIA ANTIBODIES</title><source>esp@cenet</source><creator>HEKE, STEFAN ; VEURINK, MARIEKE ; PLITZKO, MATTHIAS ; GOMBERT, NIKLAS ; KLAK, ALEXANDER ; SCHNEID, STEFAN CHRISTIAN</creator><creatorcontrib>HEKE, STEFAN ; VEURINK, MARIEKE ; PLITZKO, MATTHIAS ; GOMBERT, NIKLAS ; KLAK, ALEXANDER ; SCHNEID, STEFAN CHRISTIAN</creatorcontrib><description>The present invention refers to novel liquid pharmaceutical high-concentration formulations particularly suitable for subcutaneous administration comprising human antibodies against coagulation factor FXIa as active ingredient, especially those described in WO2013167669, which are stable as liquid formulations over a long period. The invention also refers to lyophilizates of the specified liquid formulation with reduced reconstitution time and also to the use of these formulations in the therapy and prophylaxis of thrombotic or thromboembolic disorde.
La présente invention concerne de nouvelles formulations pharmaceutiques liquides à haute concentration particulièrement appropriées pour une administration sous-cutanée comprenant des anticorps humains contre le facteur de coagulation FXIa en tant que principe actif, en particulier ceux décrits dans la demande de brevet WO2013167669, qui sont stables en tant que formulations liquides sur une longue période. L'invention concerne également des lyophilisats de la formulation liquide spécifiée avec un temps de reconstitution réduit ainsi que l'utilisation de ces formulations dans la thérapie et la prophylaxie de troubles thrombotique ou thromboembolique.</description><language>eng ; fre</language><subject>BLASTING ; DRYING ; DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM ; HEATING ; HUMAN NECESSITIES ; HYGIENE ; LIGHTING ; MECHANICAL ENGINEERING ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; WEAPONS</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200109&DB=EPODOC&CC=CA&NR=3105256A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200109&DB=EPODOC&CC=CA&NR=3105256A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HEKE, STEFAN</creatorcontrib><creatorcontrib>VEURINK, MARIEKE</creatorcontrib><creatorcontrib>PLITZKO, MATTHIAS</creatorcontrib><creatorcontrib>GOMBERT, NIKLAS</creatorcontrib><creatorcontrib>KLAK, ALEXANDER</creatorcontrib><creatorcontrib>SCHNEID, STEFAN CHRISTIAN</creatorcontrib><title>NOVEL STABLE HIGH-CONCENTRATION FORMULATION FOR ANTI-FXIA ANTIBODIES</title><description>The present invention refers to novel liquid pharmaceutical high-concentration formulations particularly suitable for subcutaneous administration comprising human antibodies against coagulation factor FXIa as active ingredient, especially those described in WO2013167669, which are stable as liquid formulations over a long period. The invention also refers to lyophilizates of the specified liquid formulation with reduced reconstitution time and also to the use of these formulations in the therapy and prophylaxis of thrombotic or thromboembolic disorde.
La présente invention concerne de nouvelles formulations pharmaceutiques liquides à haute concentration particulièrement appropriées pour une administration sous-cutanée comprenant des anticorps humains contre le facteur de coagulation FXIa en tant que principe actif, en particulier ceux décrits dans la demande de brevet WO2013167669, qui sont stables en tant que formulations liquides sur une longue période. L'invention concerne également des lyophilisats de la formulation liquide spécifiée avec un temps de reconstitution réduit ainsi que l'utilisation de ces formulations dans la thérapie et la prophylaxie de troubles thrombotique ou thromboembolique.</description><subject>BLASTING</subject><subject>DRYING</subject><subject>DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM</subject><subject>HEATING</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>LIGHTING</subject><subject>MECHANICAL ENGINEERING</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>WEAPONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHDx8w9z9VEIDnF08nFV8PB099B19vdzdvULCXIM8fT3U3DzD_IN9YGzFRz9Qjx13SI8HcEsJ38XT9dgHgbWtMSc4lReKM3NoODmGuLsoZtakB-fWlyQmJyal1oS7-xobGhgamRq5mhoTIQSABK8K1o</recordid><startdate>20200109</startdate><enddate>20200109</enddate><creator>HEKE, STEFAN</creator><creator>VEURINK, MARIEKE</creator><creator>PLITZKO, MATTHIAS</creator><creator>GOMBERT, NIKLAS</creator><creator>KLAK, ALEXANDER</creator><creator>SCHNEID, STEFAN CHRISTIAN</creator><scope>EVB</scope></search><sort><creationdate>20200109</creationdate><title>NOVEL STABLE HIGH-CONCENTRATION FORMULATION FOR ANTI-FXIA ANTIBODIES</title><author>HEKE, STEFAN ; VEURINK, MARIEKE ; PLITZKO, MATTHIAS ; GOMBERT, NIKLAS ; KLAK, ALEXANDER ; SCHNEID, STEFAN CHRISTIAN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3105256A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2020</creationdate><topic>BLASTING</topic><topic>DRYING</topic><topic>DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM</topic><topic>HEATING</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>LIGHTING</topic><topic>MECHANICAL ENGINEERING</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>WEAPONS</topic><toplevel>online_resources</toplevel><creatorcontrib>HEKE, STEFAN</creatorcontrib><creatorcontrib>VEURINK, MARIEKE</creatorcontrib><creatorcontrib>PLITZKO, MATTHIAS</creatorcontrib><creatorcontrib>GOMBERT, NIKLAS</creatorcontrib><creatorcontrib>KLAK, ALEXANDER</creatorcontrib><creatorcontrib>SCHNEID, STEFAN CHRISTIAN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HEKE, STEFAN</au><au>VEURINK, MARIEKE</au><au>PLITZKO, MATTHIAS</au><au>GOMBERT, NIKLAS</au><au>KLAK, ALEXANDER</au><au>SCHNEID, STEFAN CHRISTIAN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>NOVEL STABLE HIGH-CONCENTRATION FORMULATION FOR ANTI-FXIA ANTIBODIES</title><date>2020-01-09</date><risdate>2020</risdate><abstract>The present invention refers to novel liquid pharmaceutical high-concentration formulations particularly suitable for subcutaneous administration comprising human antibodies against coagulation factor FXIa as active ingredient, especially those described in WO2013167669, which are stable as liquid formulations over a long period. The invention also refers to lyophilizates of the specified liquid formulation with reduced reconstitution time and also to the use of these formulations in the therapy and prophylaxis of thrombotic or thromboembolic disorde.
La présente invention concerne de nouvelles formulations pharmaceutiques liquides à haute concentration particulièrement appropriées pour une administration sous-cutanée comprenant des anticorps humains contre le facteur de coagulation FXIa en tant que principe actif, en particulier ceux décrits dans la demande de brevet WO2013167669, qui sont stables en tant que formulations liquides sur une longue période. L'invention concerne également des lyophilisats de la formulation liquide spécifiée avec un temps de reconstitution réduit ainsi que l'utilisation de ces formulations dans la thérapie et la prophylaxie de troubles thrombotique ou thromboembolique.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA3105256A1 |
| source | esp@cenet |
| subjects | BLASTING DRYING DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM HEATING HUMAN NECESSITIES HYGIENE LIGHTING MECHANICAL ENGINEERING MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS WEAPONS |
| title | NOVEL STABLE HIGH-CONCENTRATION FORMULATION FOR ANTI-FXIA ANTIBODIES |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T08%3A53%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HEKE,%20STEFAN&rft.date=2020-01-09&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3105256A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |